Research programme: urinary incontinence therapy - GrunenthalAlternative Names: Urinary incontinence therapy research programme - Grunenthal
Latest Information Update: 16 Jul 2016
At a glance
- Originator Grunenthal
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Urinary incontinence
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Urinary-incontinence in Germany
- 24 Jun 2005 Preclinical trials in Urinary incontinence in Germany (unspecified route)